Hyperlipidemia: Difference between revisions
Jump to navigation
Jump to search
| Line 35: | Line 35: | ||
====[[Niacin]]==== | ====[[Niacin]]==== | ||
=====[[AIM HIGH study | | =====[[Niacin AIM HIGH study | AIM HIGH study]]===== | ||
==References== | ==References== | ||
Revision as of 14:29, 20 November 2011
For patient information click here Template:DiseaseDisorder infobox
|
Lipoprotein Disorders Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Risk factors
Screening
Target population | Screening tests | Screening frequency
Causes
Classification
Treatment
NCEP recommendations for children and adolescents with high-risk hyperlipidemia
Recommendations for drug therapy | Statins | Adjuvant therapies
Pharmacotherapy
Statins | Niacin | Fibrate | Omega-3 fatty acids===
Trial supportive data
Niacin
AIM HIGH study
References
External links
| Hyperlipoproteinemia | OMIM | GPnotebook | WebMD | Others |
|---|---|---|---|---|
| Type I | Online Mendelian Inheritance in Man (OMIM) 238600 | Template:GPnotebook | . | MeritCare |
| Type IIa | Online Mendelian Inheritance in Man (OMIM) 144400 | Template:GPnotebook | . | Merck |
| Type IIb | Template:GPnotebook | . | ||
| Type III | . | Template:GPnotebook | WebMD | Yahoo |
| Type IV | Online Mendelian Inheritance in Man (OMIM) 144600 | Template:GPnotebook | WebMD | Yahoo |
| Type V | Online Mendelian Inheritance in Man (OMIM) 144600 | Template:GPnotebook | . | . |